Drug Trial Radar · NCT07556107
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
852
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
Jun 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Bassett HealthcareAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Johns Hopkins University; Patient-Centered Outcomes Research Institute
- First posted
- Apr 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Conditions
- Infection
- Acute Kidney Injury
- Sepsis
Interventions
Piperacillin + TazobactamDrug
PT Dosing (concealed): PT dosing is standard irrespective of infection severity. 4.5 gm IV loading dose over 30 min, then 4.5 g IV over 4 hr (extended infusion) 6 hrs after the loading dose, and then q 8 hr
meropenemDrug
M dosing (concealed): M dosing depends on infection severity. 1 gm loading IV dose over 30 min, then 1 gm IV over 4 hr (extended infusion) q 8 hr (default dosing). Clinician has option to increase to 2 gm IV q 8 hr for severe infections and to decrease back to default dosing if previously chosen higher dosing is no longer deemed indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum cystatin C (Scys)Time frame: 7 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Massachusetts Chan Medical School
Worcester, Massachusetts · Not yet recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Bassett Medical Center
Cooperstown, New York · Recruiting
NY Presbyterian/Queens
Flushing, New York · Not yet recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
Medical University of South Carolina - South Carolina Clinical & Translational Research Institute
Charleston, South Carolina · Recruiting
West Virginia University
Morgantown, West Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.